|
WO2021021933A1
|
|
Isph inhibitors, and methods of making and using same
|
|
WO2020252407A1
|
|
Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
|
|
WO2020214203A1
|
|
Replication deficient adenoviral vectors for hiv vaccine applications
|
|
WO2020072371A1
|
|
Melanoma canine vaccine compositions and methods of use thereof
|
|
WO2020033797A1
|
|
Anti-follicule stimulating hormone receptor antibodies
|
|
CN112261947A
|
|
Tumor specific neoantigens and methods of use thereof
|
|
EP3793546A1
|
|
Ebna1 inhibitor crystalline forms, and methods of preparing and using same
|
|
WO2019199808A1
|
|
Engineered optimized cytokine compositions
|
|
WO2019199799A1
|
|
Humanized mouse model
|
|
US2021008043A1
|
|
Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same
|
|
US2014248305A1
|
|
Adenoviral vectors comprising partial deletions of E3
|
|
AU2010279359A1
|
|
Compositions containing JARID1B inhibitors and methods for treating cancer
|
|
AU2008317002A1
|
|
Method for identifying a compound that modulates telomerase activity
|
|
AU2006209360A1
|
|
Method and device for analysis of charged molecules by solution isoelectric focusing
|
